表紙
市場調查報告書

NADPH氧化酶4:開發中產品分析

NADPH Oxidase 4 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 374380
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
NADPH氧化酶4:開發中產品分析 NADPH Oxidase 4 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 65 Pages
簡介

本報告提供以NADPH氧化酶4為標的之治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

NADPH氧化酶4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • GenKyoTex S.A.
  • Glucox Biotech AB

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2210TDB

Summary

According to the recently published report 'NADPH Oxidase 4 - Pipeline Review, H2 2019'; NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) pipeline Target constitutes close to 6 molecules.

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - NADPH oxidase 4 is an enzyme belonging to NOX family of NADPH oxidases. NADPH Oxidase 4 is localized to non-phagocytic cells where it acts as an oxygen sensor and catalyzes the reduction of molecular oxygen to various reactive oxygen species. So formed ROS have been implicated in numerous biological functions including signal transduction, cell differentiation and tumor cell growth.

The report 'NADPH Oxidase 4 - Pipeline Review, H2 2019' outlays comprehensive information on the NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Respiratory, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Musculoskeletal Disorders, Oncology and Toxicology which include indications Idiopathic Pulmonary Fibrosis, Acute Ischemic Stroke, Atherosclerosis, Chlorine Poisoning, Diabetic Complications, Diabetic Nephropathy, Fibrosis, Gastrointestinal Radiation Toxicity, Ischemia Reperfusion Injury, Kidney Fibrosis, Liver Fibrosis, Mustard Gas (Sulfur Mustard) Poisoning, Nerve Gas Poisoning, Non-Alcoholic Steatohepatitis (NASH), Portal Hypertension, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Progressive Supranuclear Palsy, Prostate Cancer, Pulmonary Radiation Toxicity, Systemic Sclerosis (Scleroderma) and Type 2 Diabetes.

Scope

  • The report provides a snapshot of the global therapeutic landscape for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)
  • The report reviews NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Overview
  • NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Companies Involved in Therapeutics Development
  • GenKyoTex SA
  • Glucox Biotech AB
  • New Amsterdam Sciences Inc
  • OliPass Corporation
  • NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Drug Profiles
  • Antisense Oligonucleotides to Inhibit NOX4 for Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NAS-150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • setanaxib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit NOX-4 for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Dormant Products
  • NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Discontinued Products
  • NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 03, 2019: Genkyotex reports progress of Setanaxib Phase 2 investigator initiated trials
  • Jul 25, 2019: Genkyotex announces positive post-hoc analysis of PBC phase 2 trial and reports cash position at June 30, 2019
  • Jul 24, 2019: Genkyotex conference call for post-hoc analysis of Setanaxib (GKT831) PBC Ph2 trial and business update
  • Jul 22, 2019: The WHO recognizes NOX inhibitors as new therapeutic class and approves setanaxib for GKT831
  • Jul 18, 2019: Genkyotex to launch Phase II pulmonary fibrosis trial in US
  • Jul 01, 2019: Genkyotex's GKT831 prevents multiple complications of portal hypertension in preclinical model
  • Jun 24, 2019: Genkyotex announces positive final results of GKT831 trial in PBC
  • May 23, 2019: Genkyotex invites shareholders to Annual General Meeting on June 13, 2019
  • May 21, 2019: Preclinical study of GKT831 shows rapid regression of cholestatic fibrosis in model of advanced liver fibrosis
  • May 02, 2019: Genkyotex reports mixed efficacy Phase II data for PBC drug
  • Apr 08, 2019: Genkyotex to present updated interim results from Phase 2 trial of GKT831 in Primary Biliary Cholongitis at 2019 EASL International Liver Congress (ILC)
  • Mar 11, 2019: Genkyotex announces completion of 24-week treatment period of its phase 2 yrial with GKT831 in primary biliary cholangitis
  • Feb 11, 2019: Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology
  • Jan 25, 2019: Genkyotex provides update on its primary biliary cholangitis drug candidate GKT831
  • Dec 19, 2018: Genkyotex announces an extraordinary shareholders meeting to be held on January 24, 2019 at 10 am and confirms the key development milestone for GKT831 in PBC
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by GenKyoTex SA, H2 2019
  • Pipeline by Glucox Biotech AB, H2 2019
  • Pipeline by New Amsterdam Sciences Inc, H2 2019
  • Pipeline by OliPass Corporation, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019